Navigation Links
New Shire Board Member
Date:11/2/2009

DUBLIN, Ireland, November 2 /PRNewswire-FirstCall/ -- The Board of Directors of Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that Mr David Stout joined the Board as a Non Executive Director with effect from 31 October 2009.

Mr Stout has extensive pharmaceutical experience. Most recently he was President, Pharmaceutical Operations at GSK. In this position he had responsibility for pharmaceutical operations in the United States, Europe, Japan and all other International Markets. Mr Stout was also responsible for global manufacturing and global Biologics (vaccines) at GSK. Prior to that he was President of GSK's US Pharmaceuticals Business and before that SmithKline Beecham's North American Pharmaceuticals Business. Before joining SmithKline Beecham, Mr Stout worked for many years at Schering-Plough.

Mr Stout holds directorships at Allos Therapeutics, Inc, Jabil Circuit, Inc. and Airgas Inc.

Matt Emmens, Chairman of Shire commented;

"We are delighted to welcome David Stout to the Shire Board. He brings with him extensive international experience in the pharmaceutical industry, which we believe will be of great value to Shire as it continues its growth trajectory and becomes a more global company."

Notes to Editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual propert
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... patient has sepsis, a life-threatening condition in which bacteria ... too fast for antibiotics to help. A new device ... team at Harvard,s Wyss Institute for Biologically Inspired Engineering ... , "Even with the best current treatments, sepsis patients ... percent of the time," said Mike Super, Ph.D., Senior ...
(Date:9/15/2014)... Calif. , Sept. 15, 2014 ... new viral transport solution for safe ambient temperature ... to molecular testing. Importantly, the infectivity of agents in ... while maintaining the integrity of the viral nucleic ... of the recent Ebola epidemic in ...
(Date:9/15/2014)... CA (PRWEB) September 15, 2014 ... term implantable silicones for the medical device and ... silicone gel for the implantable medical device market. ... unique crosslink technology delivering a silicone gel with ... The Dual Matrix technology consists of two crosslinked ...
(Date:9/15/2014)... Sept. 15, 2014  The second annual International ... 12-18. A joint initiative of the Plasma Protein ... , IPAW is designed to: , Raise ... the contributions of plasma donors in saving and improving ... therapies and rare diseases Member companies ...
Breaking Biology Technology:Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3
... , Key ... • receptor binding assay • LEADseeker • ... The α 2 -adrenergic receptors are G protein-coupled receptors ... as renal Na + re-absorption, insulin secretion, platelet aggregation, and neurotransmitter release ...
... Key words: NK2 • GPCR ... SPA Imaging Beads , ... a family of small neuropeptides. Members of this family include peptides, substance ... hemokinin-1 (1). Neurokinins are widely distributed throughout the central and peripheral nervous ...
... Key words: formalin-fixed ... degenerate oligonucleotideprimed PCR (DOP-PCR),• Cy3/Cy5-dCTP probe labeling • comparative,genomic ... array CGH , ... Human genomic DNA isolated from formalin-fixed paraffin-embedded (FFPE) tissue ...
Cached Biology Technology:Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System 2Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System 3Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System 4Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System 2Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System 3Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System 4GenomiPhi amplification of FFPE tissue DNA for array CGH 2GenomiPhi amplification of FFPE tissue DNA for array CGH 3GenomiPhi amplification of FFPE tissue DNA for array CGH 4GenomiPhi amplification of FFPE tissue DNA for array CGH 5GenomiPhi amplification of FFPE tissue DNA for array CGH 6GenomiPhi amplification of FFPE tissue DNA for array CGH 7GenomiPhi amplification of FFPE tissue DNA for array CGH 8GenomiPhi amplification of FFPE tissue DNA for array CGH 9GenomiPhi amplification of FFPE tissue DNA for array CGH 10
(Date:9/16/2014)... fall marks a new school year, a new football ... Space Station. In September, SpaceX,s Dragon spacecraft is scheduled ... and investigations as part of the company,s fourth contracted ... will be the third suite of research investigations sponsored ... Space (CASIS). With the role of managing the U.S. ...
(Date:9/16/2014)... of interaction between viruses, bacteria, and their environment ... international collaboration between Matthew Sullivan, associate professor in ... Evolutionary Biology and Steven Hallam from the University ... "Bacteria are drivers of nutrient and energy cycles ... climate is changing, so are the environments these ...
(Date:9/16/2014)... pipeline (KXL) would likely increase oil sands extraction, according ... the non-profit organization Near Zero. The results are detailed ... includes both supporters and opponents of the pipeline. ... lead to significantly higher greenhouse gas emissions, with the ... , "This report examines three main scenarios discussed by ...
Breaking Biology News(10 mins):CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3Keystone XL would likely raise oil sands production and greenhouse gas emissions 2
... are often seen laughing and smiling, but this cheerful ... and seizures. , ,ew research in mice, ... alleviated. , Edwin Weeber, Ph.D., and colleagues reversed ... syndrome by preventing the inhibition of CaMKII, an enzyme ...
... sea levels in the centuries to come? Are we destroying ... oceans on the rise? Can aquaculture be environmentally sustainable? And ... coastal fisheries? , Most importantly, what can governments, industry and ... media are invited to join leading international researchers and government ...
... winner of the 2006 David Horrobin Prize for medical ... Assumption and No Two Alike, the article, "Parental selection: ... hairlessness and skin color" was judged to best embody ... in 2004, is awarded annually and named in honour ...
Cached Biology News:Angelman syndrome deficits rescued in mice 2Angelman syndrome deficits rescued in mice 3Are we killing the world's oceans? 2Why aren't humans furry? Stone-Age moms could be the answer 2
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
Mouse polyclonal antibody raised against a partial recombinant SYT4. NCBI Entrez Gene ID = 6860...
Mouse monoclonal antibody raised against a partial recombinant IL31RA. NCBI Entrez Gene ID = IL31RA...
...
Biology Products: